We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Bristol-Myers Squibb (BMS) and Gilead Sciences have announced an agreement to commercialize Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Canada for the treatment of HIV-1 infection in adults, subject to the approval of the product by Health Canada.
Sanofi pasteur, the vaccines arm of French drugmaker sanofi-aventis,
has announced a partnership with the Pediatric Dengue Vaccine Initiative (PDVI) to help develop and make a dengue vaccine widely available for the prevention of dengue fever, the second most widespread tropical disease after malaria.
New Zealand's Pharmaceutical Management Agency (PHARMAC) on Oct. 1 began a program to subsidize clopidogrel, which is sold under the brand name Plavix, for people with acute heart problems.
Inyx, Inc., a specialty pharmaceutical company focused on niche drug delivery technologies and products, announced that its wholly owned subsidiary, Inyx Pharma Ltd., has executed a definitive agreement to acquire Pharmapac UK Ltd., one of the leading contract pharmaceutical production and packaging providers in the United Kingdom.
Israel-based generics company Teva Pharmaceutical Industries said that it could file as many as 15 applications between 2009-2015 seeking approval for either new medicines or for new uses or stronger doses of existing drugs, according to a report.
Merck & Co Inc's Gardasil, the first vaccine to prevent cervical cancer, will be launched in most of western Europe by the end of 2006, the joint venture responsible for European marketing said on Thursday.
Eisai Co., Ltd. announced that lawsuits filed against three pharmaceutical manufacturers regarding the sales of generic versions of Selbex capsule 50mg ('Selbex'; generic name: teprenone) have been
dismissed by the Intellectual Property High Court.
Multinational drug companies have been lobbying ministers in an attempt to subvert the independent appraisal process and get their expensive new medicines approved for large-scale use in the NHS, the Guardian can reveal.
Novartis has announced it will reduce the average price of its malaria drug Coartem by more than one-third to approximately $1 per treatment in an effort to increase access to the drug in low-income countries, particularly those in Africa.